Updated
Dec. 30, 2021
Reviewed
Dec. 30, 2021

Non-Nucleoside Reverse Transcriptase Inhibitors

Doravirine (Pifeltro, DOR)

Animal Studies

Carcinogenicity

Doravirine (DOR) was not carcinogenic in long-term oral carcinogenicity studies in mice and rats at exposures up to six times and seven times, respectively, the exposure seen in humans who received the recommended dose. A statistically significant incidence of thyroid parafollicular cell adenoma and carcinoma was observed among female rats that received the high dose (which produced the sevenfold increase in exposure) of DOR; however, the incidence was similar to the incidence observed among historical controls that did not receive DOR. DOR was not genotoxic in a battery of in vitro or in vivo mutagenicity assays.1

Reproduction/Fertility

In rats, DOR did not affect fertility, reproductive performance, or early embryonic development at exposures (based on area under the curve [AUC]) that were approximately seven times the exposure seen in humans who received the recommended dose.1

Teratogenicity/Adverse Pregnancy Outcomes

No adverse embryo-fetal effects were observed in rats and rabbits at DOR exposures (based on AUC) that were approximately nine times (in rats) and eight times (in rabbits) the exposures seen in humans who received the recommended dose. Similarly, no adverse developmental findings were reported in a prenatal/postnatal study in rats at DOR exposures that were approximately nine times the exposure seen in humans who received the recommended dose.1

Placental and Breast Milk Passage

Embryo-fetal studies in rats and rabbits demonstrate placental passage of DOR. Fetal plasma concentrations observed on gestation Day 20 were up to 40% (in rabbits) and 52% (in rats) of maternal concentrations. DOR was excreted into the milk of lactating rats at concentrations that were approximately 1.5 times the maternal concentrations measured 2 hours postdose on lactation Day 14.1

Human Studies in Pregnancy

Pharmacokinetics

No pharmacokinetic studies of DOR in pregnant women have been reported.

Placental and Breast Milk Passage

Placental transfer of DOR was noted in an ex vivo dually perfused human cotyledon model with a median (interquartile range [IQR] 25–75) fetal transfer rate of 16% (12% to 18%).2

No data are available on breast milk passage of DOR in humans.

Teratogenicity/Adverse Pregnancy Outcomes

The Antiretroviral Pregnancy Registry has monitored prospectively four patients treated with DOR during the first trimester and one patient treated with DOR during the second and third trimester; one infant with first trimester exposure was noted to have a birth defect. These data are insufficient to make conclusions regarding the safety of DOR during pregnancy.

Excerpt from Table 11

Note: When using fixed-dose combination (FDC) tablets, refer to other sections in Appendix B and Table 11 in the Perinatal Guidelines for information about the dosing and safety of individual drug components of the FDC tablet during pregnancy.

Generic Name
(Abbreviation)
Trade Name
Formulation Dosing Recommendationsa Use in Pregnancy

Doravirine

(DOR)

Pifeltro

(DOR/3TC/TDF)

Delstrigo

DOR (Pifeltro):

  • 100 mg tablet

DOR/3TC/TDF (Delstrigo):

  • DOR 100 mg/3TC 300 mg/TDF 300 mg tablet

Standard Adult Doses

DOR (Pifeltro):

  • DOR 100 mg once daily with or without food

DOR/3TC/TDF (Delstrigo):

  • One tablet once daily with or without food

Pregnancy

PKs in Pregnancy:

  • No PK studies in human pregnancy.

Dosing in Pregnancy:

  • Insufficient data to make dosing recommendations.

For guidance about the use of combination ARV drug products in pregnancy, please see the specific sections on other drug components (i.e., 3TC, TDF).

No human in vivo data are available on the placental transfer of DOR, but passage is noted in an ex vivo model.

Insufficient data are available to assess for teratogenicity in humans. No evidence exists of teratogenicity in rats or rabbits.

a Individual ARV drug doses may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Antiretroviral Guidelines, Appendix B, Table 11).

Key: 3TC = lamivudine; ARV = antiretroviral; DOR = doravirine; PK = pharmacokinetic; TDF = tenofovir disoproxil fumarate

References

  1. Doravirine (Pifeltro) [package insert]. Food and Drug Administration. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210806s003lbl.pdf.
  2. Le MP, Pencole L, Peytavin G, Bouchet-Crivat F, Mandelbrot L. Placental transfer of doravirine, a recent HIV-1 NNRTI in the ex vivo human cotyledon perfusion model. J Antimicrob Chemother. 2021;76(9):2364-2367. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34151361.

Non-Nucleoside Reverse Transcriptase Inhibitors

Doravirine (Pifeltro, DOR)

Generic Name
(Abbreviation)
Trade Name
Formulation Dosing Recommendationsa Use in Pregnancy

Doravirine

(DOR)

Pifeltro

(DOR/3TC/TDF)

Delstrigo

DOR (Pifeltro):

  • 100 mg tablet

DOR/3TC/TDF (Delstrigo):

  • DOR 100 mg/3TC 300 mg/TDF 300 mg tablet

Standard Adult Doses

DOR (Pifeltro):

  • DOR 100 mg once daily with or without food

DOR/3TC/TDF (Delstrigo):

  • One tablet once daily with or without food

Pregnancy

PKs in Pregnancy:

  • No PK studies in human pregnancy.

Dosing in Pregnancy:

  • Insufficient data to make dosing recommendations.

For guidance about the use of combination ARV drug products in pregnancy, please see the specific sections on other drug components (i.e., 3TC, TDF).

No human in vivo data are available on the placental transfer of DOR, but passage is noted in an ex vivo model.

Insufficient data are available to assess for teratogenicity in humans. No evidence exists of teratogenicity in rats or rabbits.

a Individual ARV drug doses may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Antiretroviral Guidelines, Appendix B, Table 11).

Key: 3TC = lamivudine; ARV = antiretroviral; DOR = doravirine; PK = pharmacokinetic; TDF = tenofovir disoproxil fumarate

Download Guidelines